proxinium
mAbexperimentalADC
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Dec 1, 2005 (NCT00412776)
Timeline
Indications
Mechanism of action
- Epithelial cell adhesion moleculeBINDING AGENT
EPCAM binding agent
Single chain anti-EpCAM fragment fused with Pseudomonas exotoxin. Designed to target cancer cells expressing EpCAM, which internalize the recombinant fusion protein once it is bound. Within the cell, the payload dissociates from the single chain fragment and is then able to exert its cell-killing activity.
- Elongation factor 2INHIBITOR
Elongation factor 2 inhibitor
- Epithelial cell adhesion moleculeINHIBITOR
EPCAM inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- Pseudomonas exotoxin A
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109260 ↗
- ChEMBLCHEMBL1743052 ↗
Also known as
- h11 scfv
- oportuzumab monatox
- oportuzumab monatox
- proxinium
- proxinium
- proxinium, vicinium
- vb4-845
- vb4-845
- vicinium
- vicinium
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03258593 | Phase 1 | Jun 7, 2018 | National Cancer Institute (NCI) |
| NCT02449239 | Phase 3 | Aug 1, 2015 | Viventia Biotech Inc. |
| NCT00462488 | Phase 2 | Mar 1, 2007 | Viventia Biotech Inc. |
| NCT00272181 | Phase 2 | Jan 1, 2006 | Viventia Biotech Inc. |
| NCT00412776 | Phase 2/Phase 3 (Phase 3) | Dec 1, 2005 | Viventia Biotech Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Viventia Biotech Inc. | For profit | 4 | 4 | 2 | 2005 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1